While oral semaglutide is not approved for weight reduction, its injectable form shares which similar pharmacological properties has received FDA approval for the management of obesity. The clinical development program for oral semaglutide has shown potential benefits in body weight reduction in addition to a plethora of benefits. This real-world longitudinal study from a comprehensive diabetes centre in Kerala, India assessed the effect of weight loss on HbA1c levels in T2D using Oral Semaglutide, with follow-up data from March 2022 to July 2023 in 196 subjects. Subjects were divided into three groups based on weight loss: 0-5%, 5-10%, and over 10%. Analysis was conducted using R version 4.3.1, with a significance level set at 5%. In the cohort with a weight reduction of 0 to 5%, there was a significant HbA1c reduction of 1.13% (95% CI = 0.13 to 2.14, p = 0.032). For those who lost 5 to 10% of their weight, HbA1c decreased by 1.3% (95% CI = 0.32 to 2.28, p = 0.015). The most substantial HbA1c reduction, 1.98% (95% CI = 1.11 to 2.85, p = 0.002), was observed in the group that lost more than 10% of their weight. (Figure) This study demonstrates that oral Semaglutide effectively reduces HbA1c levels in T2DM patients, particularly in those with significant weight loss. These findings highlight its potential dual benefit in glycemic control and weight management in T2DM therapy.
J. Kesavadev: None. A. Shankar: None. S.R. Joshi: Consultant; Twin Health, Marico, Franco Indian, Zydus Cadila, Glenmark Pharmaceuticals. Other Relationship; Novo Nordisk, Sanofi, MSD, Abbott Nutrition, Abbott, Biocon, Alkem, USV Private Limited, Boehringer-Ingelheim. A. Ashik: None. S. Yasmin: None. A. Basanth: None. S. Raj K: None. S. Jothydev: None.
